Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Express Scripts
Johnson and Johnson
Harvard Business School
Moodys

Last Updated: November 27, 2022

CLINICAL TRIALS PROFILE FOR TENOFOVIR ALAFENAMIDE FUMARATE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Tenofovir Alafenamide Fumarate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00036634 ↗ A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients Completed Gilead Sciences Phase 1/Phase 2 2002-03-01 This study evaluated two doses of tenofovir alafenamide versus tenofovir disoproxil fumarate (tenofovir DF).
NCT01497899 ↗ Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults Completed Gilead Sciences Phase 2 2011-12-28 The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya®; E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (Stribild®; E/C/F/TDF) FDC in HIV-1 infected, antiretroviral treatment-naive adults.
NCT01565850 ↗ D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults Completed Gilead Sciences Phase 2 2012-04-01 This study is to evaluate the safety and efficacy darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed dose combination (FDC) tablet versus darunavir (DRV)+cobicistat (COBI)+emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) in HIV-1 infected, antiretroviral treatment-naive adults as determined by the achievement of HIV-1 RNA < 50 copies/mL at Week 24.
NCT01780506 ↗ Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults Completed Gilead Sciences Phase 3 2012-12-26 The primary objective of this study is to evaluate the efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) versus elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) FDC in HIV-1 positive, antiretroviral treatment-naive adults.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Tenofovir Alafenamide Fumarate

Condition Name

Condition Name for Tenofovir Alafenamide Fumarate
Intervention Trials
HIV 13
Chronic Hepatitis B 11
HIV Infections 9
HIV-1 Infection 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Tenofovir Alafenamide Fumarate
Intervention Trials
Hepatitis B 29
Hepatitis 26
Hepatitis A 19
Hepatitis B, Chronic 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Tenofovir Alafenamide Fumarate

Trials by Country

Trials by Country for Tenofovir Alafenamide Fumarate
Location Trials
United States 371
China 73
Canada 54
United Kingdom 23
France 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Tenofovir Alafenamide Fumarate
Location Trials
California 26
Florida 21
New York 19
Texas 18
Michigan 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Tenofovir Alafenamide Fumarate

Clinical Trial Phase

Clinical Trial Phase for Tenofovir Alafenamide Fumarate
Clinical Trial Phase Trials
Phase 4 21
Phase 3 26
Phase 2 10
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Tenofovir Alafenamide Fumarate
Clinical Trial Phase Trials
Completed 31
Recruiting 22
Not yet recruiting 11
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Tenofovir Alafenamide Fumarate

Sponsor Name

Sponsor Name for Tenofovir Alafenamide Fumarate
Sponsor Trials
Gilead Sciences 34
Third Affiliated Hospital, Sun Yat-Sen University 5
National Institute of Allergy and Infectious Diseases (NIAID) 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Tenofovir Alafenamide Fumarate
Sponsor Trials
Other 75
Industry 44
NIH 4
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Baxter
Moodys
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.